1. Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers
- Author
-
Woo Joo Kim, Sung Eun Lee, Hee Jin Cheong, Won Suk Choi, Joon Young Song, Su Hyun Kim, Young Kyung Yoon, Ji Yun Noh, Dae Won Park, Jang Wook Sohn, Sung Ran Kim, and Min Ja Kim
- Subjects
myalgia ,Adult ,Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Health Personnel ,Brief Communication ,Preventive & Social Medicine ,Viral vector ,03 medical and health sciences ,Health personnel ,0302 clinical medicine ,Internal medicine ,Health care ,Medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Safety monitoring ,Aged ,Surveillance ,Adverse Event ,business.industry ,SARS-CoV-2 ,Vaccination ,COVID-19 ,General Medicine ,Middle Aged ,Female ,medicine.symptom ,Safety ,business ,Vaccine - Abstract
Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred., Graphical Abstract
- Published
- 2021